Protalex (OTCMKTS:PRTX – Get Rating) and Science 37 (NASDAQ:SNCE – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Profitability
This table compares Protalex and Science 37’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protalex | N/A | N/A | N/A |
| Science 37 | -183.86% | -72.19% | -58.73% |
Earnings & Valuation
This table compares Protalex and Science 37’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protalex | N/A | N/A | N/A | N/A | N/A |
| Science 37 | $65.55 million | 0.50 | -$50.99 million | ($1.03) | -0.27 |
Analyst Recommendations
This is a summary of current ratings and target prices for Protalex and Science 37, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protalex | 0 | 0 | 0 | 0 | N/A |
| Science 37 | 0 | 1 | 4 | 0 | 2.80 |
Science 37 has a consensus target price of $3.50, suggesting a potential upside of 1,150.00%. Given Science 37’s higher probable upside, analysts clearly believe Science 37 is more favorable than Protalex.
Insider & Institutional Ownership
50.8% of Science 37 shares are owned by institutional investors. 80.0% of Protalex shares are owned by company insiders. Comparatively, 7.3% of Science 37 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
About Protalex
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
About Science 37
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Protalex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex and related companies with MarketBeat.com's FREE daily email newsletter.
